Abstract
In 3 patients with low-grade astrocytomas clinical pharmacology of interferon-β (107 U/mg protein) was investigated. Interferon-β with escalating dosage (2.3, 6.9, 23, 69 X 106 U/patient) was given to each patient in 4 infusions at weekly time intervals. In these patients dose-dependant plasma-levels of interferon-β of up to 5800 IU/ml were achieved. Plasma concentrations showed a biphasic decline (T 11/2 : 0.095-0.49hrs and T 212 : 5–14.5hrs). Side effects were: mild fatigue, myalgia, tachycardia, hypertension, and fever; the latter was well controlled by pretreatment application of paracetamol. Hematological changes included lymphopenia (2–6 hrs after infusion) and granulocytosis (3–6 hrs after infusion). Natural Killer cell activity was also monitored: 6 hours after infusion a drop of activity — not clearly dose dependant — was observed to a minimum of 1% pretreatment activity; 24 hrs after infusion activity increased up to a maximum of 400%. In this phase I study high biological activity of interferon-β could be detected in plasma of astrocytoma patients — clinical tolerance was good and only mild toxicity was observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Isaacs A, Lindenmann J: Virus interference: The interferon. Proc Roy Soc Ser 147: 258–267, 1957.
Stewart WE: The Interferon System. Springer, Vienna, 1980.
Balkwil FR, Oliver RT: Growth inhibitory effects of interferons on normal and malignant human hematopoetic cells. Int J Canc 20: 500–505, 1977.
Linn SL, Tso PO, Hollenberg MD: The effects of interferon on epidermal growth factor. Biochem Biophys Res Comm 96: 168–174, 1980.
Inglot AD, Oleszak E, Kisielow B: Antagonism in action between mouse or human interferon and platelet growth factor. Arch Virol 63: 291–296, 1980.
Herberman RR, Ortaldo JR, Bonnard GD: Augmentation by interferon of human natural and antibody dependant cellmediated cytotoxicity. Nature (London) 277: 221–223, 1979.
Borashed D, Tagliabue A: Interferon induced enhancement of macrophage mediated cytolysis and its difference from activation by lymphokines. Europ J Immunol 11: 110–114, 1981.
Degre M, Rollak H: Influence of interferon on the in-vivo phagocytic activity of the reticuloendothelial system cells. J Ret End Soc 25: 489–493, 1979.
Kimshi A, Shore A, Revel M: Regulation of lymphocyte mitogenesis by (2–5) oligo-isoadenylate. Nature 282: 849–851, 1979.
Brodeur BR, Merigan TC: Mechanisms of the suppressive effect of interferon on antibody synthesis in vivo. J Immunol 114:1323–1327,1975.
Hokland M, Heron I, Berg K: Increased expression ofβ2-micro globulin and histocompatibility antigens on human lymphoid cells induced by interferon. J Interferon Res 1: 483–494, 1981.
Pfeffer LM, Landsberger FR, Tamm I: Beta interferon induced time dependent changes in the plasma membrane lipid bilayer of cultured cells. J interferon Res. 1: 613–620, 1981.
Strander H, Cantell K, Ingemarson S, Jacobson PA, Nielsson U, Soderberg G: Interferon treatment of osteogenic sarcoma-a clinical trial. NIH and Fogarthy Int Cent Adv Stud 28, 1977.
Walker MD, Alexander EJ, Hunt WE et al.: Evaluation of BNCU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49: 333–356, 1978.
Sano K, Shitara N, Takakura K: Interferon productivity of human lymphocytes with the induction of Poly-I-C in cases of malignant glioma. In: Spec Neurosurg Techn Springer 1979.
Bogdahn U: Chemosensitivity of malignant human brain tumors. J Neuro Onc 1: 149–166, 1983.
Lundblatt D, Lundgren E: Block of a glioma cell line in S by interferon. Int J Canc 27: 749–754, 1981.
Bradley NJ, Darling JL, Oktar N et al.: The failure of human leukocyte interferon to influence the growth of human glioma cell populations: in-vitro and in-vivo studies. Br J Canc 48: 819–825, 1984.
Nagai M, Arai T, Ueda Y, Kasage S et al.: Interferon therapy for malignant brain tumors. 39th Ann Meet Jap Neurol Soc 1980.
Havell EA, Vilcek J: Production of high-titered interferon in cultures of human diploid cells. Ant Micr Ag Chem 12: 467–484, 1972.
Edy VG, Billiau A, DeSomer P: Purification of human fibroblast interferon by zinc-chelat affinity chromatography. J Biol Chem 252: 5934–5935, 1977.
Finter NB: Dye-uptake methods for assessing viral cytopathogenicity and their application to interferon assays. J gen Virol 5: 419–427, 1969
Fleischer B, Bogdahn U: Growth of antigen specific, HLA restricted T lymphocyte clones from cerebrospinal fluid. Clin exp Immunol 52: 38–44, 1983.
Hilfenhaus J, Damm H, Hofstätter T et al.: Pharmacokinetics of human interferon-β in monkeys. J Int Res 3: 427–436, 1981.
Billiau A, DeSomer P, Edy V et al.: Human fibroblast interferon for clinical trials. Antimicrob. Agents Chem. 14: 56–63, 1979.
Treuner J, Danneker G, Joester K et al.: Pharmacological aspects of clinical stage I/II trials with humanβ-interferon in children. J Int Res 3: 373–380, 1981.
Horning SJ, Levine JF, Meyer M et al.: Phase I study of human leukocyte interferon in patients with advanced cancer. J Biol Resp Mod 2: 47–56, 1983.
Scott DM, Secha DS, Flowers D et al.: Toxicity of interferon. Br Med J 282: 1345–1348, 1981.
Rohatiner AZS, Prior PF, Burton AC et al: Central nervous system toxicity of interferon. Br J Canc 47: 419–422, 1983.
Pape GR, Adam MR, Eisenburg J et al.: Kinetics of natural cytotoxicity in patients treated with human fibroblast interferon. Canc Imm Immunother 11: 1–6, 1981.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bogdahn, U., Fleischer, B., Hilfenhaus, J. et al. Interferon-β in patients with low-grade astrocytomas — A phase I study. J Neuro-Oncol 3, 125–130 (1985). https://doi.org/10.1007/BF02228888
Issue Date:
DOI: https://doi.org/10.1007/BF02228888